CURRICULUM VITAE
Mandana Kamgar MPH, MD
Mandana Kamgar MPH, MD
Associate Professor
Department of Medicine
Division of Medicine Hematology Oncology
Department of Medicine
Division of Medicine Hematology Oncology
OFFICE ADDRESS: |
9200 West Wisconsin Avenue |
Milwaukee, WI 53226 |
EDUCATION: |
2003 - 2010 MD, Tehran University of Medical Sciences, Tehran, Iran |
2007 - 2010 MPH, Tehran University of Medical Sciences, Tehran, Iran |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
2011 - 2013 Research Fellow, Internal Medicine, Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA |
2013 - 2016 Resident, Internal Medicine, John Stroger Jr. Hospital of Cook County, Chicago, IL |
2016 - 2019 Fellow, Internal Medicine, Hematology and Oncology, Karmanos Cancer Center/Wayne State University, Detroit, MI |
FACULTY APPOINTMENTS: |
08/2019 - 06/2024 Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI |
08/2020 - 06/2024 Assistant Professor, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI |
07/2024 - Present Associate Professor, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI |
07/2024 - Present Associate Professor, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI |
HOSPITAL STAFF PRIVILEGES: |
2019 - Present Attending Physician, Hematology and Oncology, Froedtert Memorial Lutheran Hospital, Milwaukee, WI 53226 |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Internal Medicine | 2016 | 2026 |
Medical Oncology | 2019 | 2029 |
Hematology | 2019 | 2029 |
Licensure | Number | Issue Date | Expiration |
Chicago License | 125063676 | 2013 | 2016 |
Michigan License | 301109657 | 2016 | 2019 |
Wisconsin License | 70759-20 | 2019 | 10/31/2027 |
AWARDS AND HONORS: |
2012 Young Investigator Award, American Society of Transplantation |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
2017 - Present American Society of Clinical Oncology (Member) |
2019 - Present The Alliance for Clinical Trials in Oncology (Member) |
2021 - Present American Association of Cancer Research (Member) |
2022 - Present Medical College of Wisconsin Cancer Center (Member) |
2022 - Present Wisconsin Association of Hematology and Oncology (WAHO) (Member) |
2022 - Present Pancreatic Cancer Action Network (PanCAN) (Member) |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Ad-Hoc Reviewer |
03/2020 - 04/2020 Invited external reviewer, Clinical and Translational Science Awards (CTSA) External Reviewer Exchange Consortium (CEREC); Ohio State University (OSU) CCTS Pilot Program |
2020 Invited external reviewer, Advancing a Healthier Wisconsin (AHW); Basic, Clinical and Translational Research Pathway |
2020 Invited reviewer, Scientific Reports |
11/2022 - 12/2022 Invited external reviewer, Department of Defense (DOD) Congressionally Directed Medical Research Program (CDMRP); Pancreatic Research Program (PCarRP) Idea Development Award (IDA) |
2022 Invited reviewer, JCO Precision Oncology |
2022 Invited reviewer, Journal of National Comprehensive Cancer Network (JNCCN) |
2023 Invited Reviewer, Lancet Oncology |
04/18/2025 Trainee symposium poster judge, Cancer Center Annual Trainee Symposium |
05/2025 Invited reviewer :MCWCC Pilot Grant application |
12/2025 Journal of Clinical Oncology |
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
08/2019 - Present Member, Pancreas Club, Medical College of Wisconsin |
08/2019 - Present Member, Gastrointestinal Disease Oriented Team, Medical College of Wisconsin |
02/25/2022 - Present Member, Precision Oncology Molecular Tumor Board, Medical College of Wisconsin |
2022 - Present Member, Data Safety Monitoring Committee (DSMC), Medical College of Wisconsin |
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
2019 - Present Member, GI Committee, The Alliance of Clinical Trials in Oncology |
2022 - Present Member, GI Surgery Working Group, Alliance of Clinical Trials in Oncology |
2022 - Present Member, PanCan Precision Promise Clinical Trial Consortium, Pancreatic Cancer Action Network (PanCAN) |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
International |
Mandana Kamgar, GI ASCO Update, 11th Annual MCW LaBahn Pancreatic Cancer Symposium, Virtual, 01/11/2022 |
Mandana Kamgar, Co-Chair of Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract, 2022 ASCO Gastrointestinal Cancer Symposium, SanFrancisco, CA, 01/2022 |
Mandana Kamgar, Non-invasive Liquid Biopsy Techniques (PANEL), Precision Medicine World Conference 2023, Silicon Valley, CA, 01/26/2023 |
Mandana Kamgar, Updates from GI ASCO, 12th Annual MCW LaBahn Pancreatic Cancer Symposium, Milwaukee, WI, 01/27/2023 |
National |
Mandana Kamgar, Peripheral Neuropathy after Breast Cancer: An Analysis of Data from the Women’s Health Initiative Life and Longevity After Cancer Cohort, Women’s Health Initiative Life and Longevity After Cancer (WHI LILAC) Webinar, Virtual, 04/27/2020 |
Regional |
Mandana Kamgar, Targeted Adjuvant Therapy after Total Neoadjuvant Therapy in High-Risk Pancreatic Cancer (TATOO), Seena Magowitz Foundation, Power Of Us Event 2023, Milwaukee, WI, 08/18/2023 - 08/20/2023 |
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer with High-Risk of Cancer Recurrence (PROTECT-PANC)., MCW Pancreatic
Cancer Symposium: Bench to Bedside., 08/02/2024 - 08/02/2014 |
Mandana Kamgar, Pancreatic Ductal Adenocarcinoma (PDAC), Best of ASCO 2025, Milwaukee, 07/26/2025 |
Mandana Kamgar, Precision Oncology in Pancreatic Ductal Adenocarcinoma, Real-world Experience., Celebrating 10 Years of Excellence in Wisconsin Precision Oncology, Madison, Wisconsin, 09/26/2025 |
Local |
Mandana Kamgar, Comprehensive molecular profiling of patients with pancreatic adenocarcinoma: A single institution’s experience, Molecular Tumor Board, Karmanos Cancer Institute, Detroit, 2018 |
Mandana Kamgar, Precision Medicine for Pancreatic Cancer, MCW 2020 Surgical Oncology Symposium, Virtual, 10/23/2020 |
Mandana Kamgar, GI ASCO Update, 10th Annual MCW Pancreatic Cancer Virtual Symposium, Virtual, 01/22/2021 |
Mandana Kamgar, ASCO Updates and Current Metastatic Clinical Trials, 2021 ASCO Pancreatic Cancer Review & Clinical Trials at MCW, Virtual, 06/21/2021 |
Mandana Kamgar, Thomas McFall, MEK-inhibitor Therapy in Pancreatic Ductal Adenocarcinoma, Surgery Grand Rounds, Medical College of Wisconsin, Milwaukee, Wisconsin, 05/29/2024 |
Mandana Kamgar, Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer with High-Risk of Cancer Recurrence (PROTECT-PANC)., MCW Pancreatic
Cancer Symposium: Bench to Bedside, Medical College of Wisconsin, 08/02/2024 |
Mandana Kamgar, Pancreatic adenocarcinoma treatment: from bedside to bench and back, Pancreas Club, Medical College of Wisconsin, 10/10/2024 |
Mandana Kamgar, GI ASCO 2025 updates, 2025 January Pancreatic Cancer Symposium, Medical College of Wisconsin, 01/31/2025 |
Mandana Kamgar, Thomas McFall, Mutant and Wildtype RAS Crosstalk as Determinants of Sensitivity to Targeted Therapies in Pancreatic Ductal Adenocarcinoma, Hematology and Oncology Division Grand Rounds, Medical College of Wisconsin, Milwaukee, Wisconsin, 07/10/2025 |
COMMITTEE SERVICE: |
Medical College of Wisconsin |
05/17/2021 - 01/26/2022 Member, Precision Oncology Faculty Search Committee |
2022 - Present Member, Data Safety Monitoring Committee (DSMC) |
MCW TEACHING ACTIVITIES: |
Medical Student Education |
2025 Evolving Role of Precision Oncology in Pancreatic Ductal Adenocarcinoma (PDAC); lecture for students in the Precision Medicine Master’s program |
Resident and Fellow Education |
08/2018 - Present Outpatient Gastrointestinal Clinic Preceptor: I precept medical and surgical oncology fellows and students in clinic |
05/13/2020 "Non-colorectal Gastrointestinal (GI) Oncology" for Internal Medicine Board |
10/27/2020 "Pancreatic Ductal Adenocarcinoma (PDAC), Diagnosis and Management", Didactic lecture for Hematology/Oncology fellows at MCW |
10/20/2021 "Pancreatic Ductal Adenocarcinoma (PDAC), Diagnosis and Management", Didactic lecture for Hematology/Oncology fellows at MCW |
05/03/2022 "Non-colorectal Gastrointestinal (GI) Oncology" for Internal Medicine Board |
11/29/2023 "Pancreatic Ductal Adenocarcinoma (PDAC), Diagnosis and Management", Didactic lecture for Hematology/Oncology fellows at MCW |
08/25/2025 Pancreatic Ductal Adenocarcinoma (PDAC), Diagnosis and Management; Lecture for Hematology/Oncology Fellows |
Community/Lay Public |
11/11/2020 "Metastatic Treatment and HRI-AX-CL Trial" session as part of November Pancreatic Cancer Awareness Lecture Series |
12/02/2020 Lecture titled "Understanding Pancreatic Cancer" as part of "My Health Classes" for the community |
11/16/2023 Series"What is Pancreatic Cancer" as part of November Pancreatic Cancer Awareness Lecture Series |
EXTRAMURAL TEACHING: |
Medical Student Education |
09/21/2024 Meical College of Wisconsin, From the Bench to Bedside: Careers in Oncology; MCW Cancer Center
Careers in Clinical Oncology and Cancer Research Symposium |
COMMUNITY SERVICE ACTIVITIES: |
10/28/2024 Pancreatic Ductal Adenocarcinoma (PDAC), Diagnosis and Management: Medical Oncology fellow didactic lecture, MCW |
11/11/2024 Pancreatic Cancer: Biology, Diagnosis, and Treatment, As part of lecture series for Pancreatic Cancer November Awareness |
COMMUNITY OUTREACH, AWARENESS AND MEDIA INTERVIEWS: |
11/30/2020 “Pancreatic Cancer Awareness” episode - The Word on Medicine Podcast; Invited Expert Interview |
02/25/2022 “Expert Point of View – KRYSTAL-1 Trial” – The ASCO Post; Invited Expert Interview |
07/01/2022 "Targeting the KRAS mutation for more effective cancer treatment" episode - Voice of Pancreatic Cancer Podcast, Seena Magowitz Foundation; Invited Expert Interview |
11/26/2022 "Pancreatic Cancer” episode - The Word on Medicine Podcast; Invited Expert Interview |
12/03/2022 "Could What you eat fight cancer? Medical College of WIsconsin Joins New Clinical trial", Segment on TMJ4 News Milwaukee; Invited Expert Interview (conducted by Ubah Ali) |
12/05/2022 "Medical Food for the Dietary Management of Metastatic Pancreatic Cancer" at the MCW; TMJ4 TV channel. Invited Expert Interview |
02/17/2023 "Precision Nutrition: Dietary Management of Metastatic Pancreatic Cancer" episode, Clinical & Translational Science Institute (CTSI) Discovery Radio; Invited Expert Interview (Conducted by Bryan B. Belmer) |
11/18/2023 “Pancreatic Cancer” episode - The Word on Medicine Podcast; Invited Expert Interview |
11/23/2024 Radio Show: "Pancreatic Cancer” episode - The Word on Medicine Podcast; Invited Expert Interview |
02/2025 MEK inhibitor-based therapy for metastatic pancreatic cancer with KRAS G12R mutations, GI ASCO 2025. Interview by Emily Menendez, Associate director of GI Oncology Now |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Jamali A#, Kamgar M#, Massarrat S, Sotoudeh M, Larijani B, Adler G, Seufferlein T. Pancreatic Cancer: State of the Art and Current Situation in the Islamic Republic of Iran Govaresh. 2009;14(3):189-197.
# Co-first authorship |
2. Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, Kamgar M, Gouya MM, Abbasi M. Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health. 2009 May 29;9:167. PMCID: PMC2697989 |
3. Esteghamati A, Khalilzadeh O, Mohammad K, Meysamie A, Rashidi A, Kamgar M, Abbasi M, Asgari F, Haghazali M. Secular trends of obesity in Iran between 1999 and 2007: National Surveys of Risk Factors of Non-communicable Diseases. Metab Syndr Relat Disord. 2010 Jun;8(3):209-13. |
4. Esteghamati A, Khalilzadeh O, Rashidi A, Kamgar M, Meysamie A, Abbasi M. Physical activity in Iran: results of the third national surveillance of risk factors of non-communicable diseases (SuRFNCD-2007). J Phys Act Health. 2011 Jan;8(1):27-35. |
5. Kamgar M, Huang E, Kamgar M, Nata N, Leeaphorn N, Kalantar-Zadeh K, Bunnapradist S. Zero-mismatch deceased-donor kidney versus simultaneous pancreas-kidney transplantation. Transplantation. 2012 Oct 27;94(8):822-9. |
6. Nata N, Huang E, Kamgar M, Leeaphorn N, Mehrnia A, Kalantar-Zadeh K, Bunnapradist S. Kidney failure requiring kidney transplantation after pancreas transplant alone. Clin Transpl. 2013:45-52. |
7. Huang E, Parke C, Mehrnia A, Kamgar M, Pham PT, Danovitch G, Bunnapradist S. Improved survival among sickle cell kidney transplant recipients in the recent era. Nephrol Dial Transplant. 2013 Apr;28(4):1039-46. |
8. Wiseman AC, Huang E, Kamgar M, Bunnapradist S. The impact of pre-transplant dialysis on simultaneous pancreas-kidney versus living donor kidney transplant outcomes. Nephrol Dial Transplant. 2013 Apr;28(4):1047-58. |
9. Jiang Y, Huang E, Mehrnia A, Kamgar M, Pham PT, Ogunorunyinka O, Brown I, Danovitch GM, Bunnapradist S. Can aminotransferase-to-platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients? Nephrol Dial Transplant. 2014 Jun;29(6):1247-52. |
10. Leeaphorn N, Sampaio MS, Natal N, Mehrnia A, Kamgar M, Huang E, Kalantar-Zadeh K, Kaplan B, Bunnapradist S. Renal Transplant Outcomes in Waitlist Candidates with a Previous Inactive Status Due to Being Temporarily Too Sick. Clin Transpl. 2014:117-24. |
11. Mpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. Cancers (Basel). 2019 Nov 29;11(12). PMCID: PMC6966587 |
12. Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al Hallak MN, Tesfaye A, Kim S, Shidham V, Ramzi M, Philip PA. Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Clin Cancer Res 2019 Dec 12 PMID: 31831564 12/14/2019 |
13. Khan HY, Mpilla GB, Sexton R, Viswanadha S, Penmetsa KV, Aboukameel A, Diab M, Kamgar M, Al-Hallak MN, Szlaczky M, Tesfaye A, Kim S, Philip PA, Mohammad RM, Azmi AS. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Cancers (Basel). 2020 Mar 22;12(3). PMCID: PMC7140111 |
14. Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery. 2020 Sep;168(3):440-447. |
15. Krepline AN, Geurts JL, George B, Kamgar M, Madhavan S, Erickson BA, Hall WA, Griffin MO, Evans DB, Tsai S, Kim RY. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Surgery. 2021 Mar;169(3):629-635. |
16. Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Ann Surg Oncol. 2021 Apr;28(4):2246-2256. |
17. Kamgar M, Greenwald MK, Assad H, Hastert TA, McLaughlin EM, Reding KW, Paskett ED, Bea JW, Shadyab AH, Neuhouser ML, Nassir R, Crane TE, Sreeram K, Simon MS. Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Med. 2021 Oct;10(19):6666-6676. PMCID: PMC8495292 |
18. Saif A, Verbus E, Erickson B, Kamgar M, Tsai S, Evans D, Hernandez JM, Hall WA. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma. Ann Surg Oncol. 2023 Feb;30(2):688-690. PMCID: PMC10688344 |
19. Khan HY#, Kamgar M#, Aboukameel A, Bannoura S, Chung BY, Li Y, Hallak MNA, Philip PA, Tsai S, Luther S, Hall WA, Azmi AS. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Adv Radiat Oncol. 2023;8(1):101122. PMCID: PMC9720358; # Co-first authorship |
20. Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Ann Surg Oncol. 2023 May;30(5):3013-3021. |
21. Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B. Comprehensive genomic profiling: Does timing matter? Front Oncol. 2023;13:1025367. PMCID: PMC9971445 |
22. Sreeram K, Seaton R, Greenwald MK, Kamgar M, Assad H, Baird T, Schwartz AG, Ruterbusch J, Simon MS. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort. Cancer Causes Control. 2023 May;34(5):459-468. PMCID: PMC10373434 |
23. Thalji SZ, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Chisholm P, Kulkarni N, Doucette S, Evans DB, Tsai S. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. J Surg Oncol. 2023 Jul;128(1):41-50. |
24. Thalji SZ, Fernando D, Dua KS, Madhavan S, Chisholm P, Smith ZL, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Evans DB, Tsai S. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Ann Surg. 2023 Dec 01;278(6):e1224-e1231. |
25. de Ortiz de Choudens S, Visotcky A, Banerjee A, Aldakkak M, Tsai S, Evans DB, Christians KK, Clarke CN, George B, Shreenivas A, Kamgar M, Chakrabarti S, Dua KS, Khan AH, Madhavan S, Erickson BA, Hall WA. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Cancer Med. 2024 Jan;13(1):e6582. PMCID: PMC10807686 |
26. George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2024 May;166(5):859-871.e3. |
27. Mehdi M, Szabo A, Shreenivas A, Thomas JP, Tsai S, Christians KK, Evans DB, Clarke CN, Hall WA, Erickson B, Ahmed G, Thapa B, McFall T, George B, Kurzrock R, Kamgar M. Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case series. Ther Adv Med Oncol. 2024;16:17588359241253113. PMCID: PMC11104030 |
28. Mody J, Kamgar M. Pancreatic Adenocarcinoma with Co-Occurrence of <i>KRAS</i> and <i>EGFR</i> Mutations: Case Report and Literature Review. Case Rep Oncol. 2024;17(1):399-406. PMCID: PMC10907001 |
29. Jameson GS, Hosein PJ, Pierce E, Kamgar M, Gordon MS, Snyder C, Roe DJ, Wertheim BC, Davey M, Barrett MT, Von Hoff DD, Borazanci E. Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer Cancer Medicine. June 2024;13(12). |
30. Bodeker KL, Smith BJ, Berg DJ, Chandrasekharan C, Sharif S, Fei N, Vollstedt S, Brown H, Chandler M, Lorack A, McMichael S, Wulfekuhle J, Wagner BA, Buettner GR, Allen BG, Caster JM, Dion B, Kamgar M, Buatti JM, Cullen JJ. A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biol. 2024 Nov;77:103375. PMCID: PMC11491967 |
31. Beltran Ponce SE, Small CJ, Ahmad T, Patel K, Tsai S, Kamgar M, George B, Kharofa JR, Saeed H, Dua KS, Clarke CN, Aldakkak M, Evans DB, Christians K, Paulson ES, Erickson B, Hall WA. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Pract Radiat Oncol. 2025;15(1):e47-e56. |
Books, Chapters, and Reviews |
1. Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018 Feb;18(2):131-148. PMCID: PMC6121777 |
2. Philip PA, Kamgar M (2019).'How I Treat Resectable Pancreatic Cancer With Adjuvant Therapy', in T Bekaii-Saab, B El-Rayes, T Pawlik (ed.) Handbook of Gastrointestinal Cancers: Evidence-Based Treatment and Multidisciplinary Patient Care: "Springer Publishing" 183-190 |
3. Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm. Cancers (Basel). 2020 Jul 24;12(8). PMCID: PMC7465131 |
4. Al-Qambar B, Chaker M, Kamgar M, Tesfaye A, Uwe-Wagner K, Azmi AS. Protocols in genetic mice models of pancreatic cancer Animal Models in Cancer Drug Discovery. 17 April 2019:107-123. |
5. Kamgar M, Chakrabarti S, Shreenivas A, George B. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Surg Oncol Clin N Am. 2021 Oct;30(4):673-691. |
6. Hall WA, Kamgar M, Erickson BA, Ponce SB, Tsai S, Nevalainen MT, Christians KK, George B, Dua KS, Khan AH, Evans DB, Azmi AS. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Cancer Metastasis Rev. 2021 Sep;40(3):879-889. PMCID: PMC8767496 |
7. Chakrabarti S, Kamgar M, Mahipal A. Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers (Basel). 2022 May 24;14(11). PMCID: PMC9179239 |
8. Kamgar M, Korn WM. Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers Textbook of Gastrointestinal Oncology. 1 January 2019:613-631. |
Editorials, Letters To Editor, Other |
1. Evans DB, Kamgar M, Tsai S. Goals of Treatment Sequencing for Localized Pancreatic Cancer. Ann Surg Oncol. 2019 Nov;26(12):3815-3819. |
2. Kamgar M, Ko AH. Bridging the Gap: Molecular Profiling to Guide Treatment Selection in Metastatic Pancreatic Cancer. J Clin Oncol. 2025 Nov;43(31):3334-3338. |
Non-Refereed Journal Publications/Original Papers |
1. Kothari A, Thalji S, Aldakkak M, SenthilKumar G, Belbahri M, Shaik T, Jaraczewski T, Merrill J,
Ramamurthi A, Banerjee A, Taylor B, Kamgar M, George B, Erickson B, Hall WA, Lytle N, Seo Y,
Christians K, Clarke CN, Evans DB,Tsai S. AI-Derived Electronic Tumor Marker (e19-9) Can Measure Treatment Response and Outcomes in CA19-9 Non-Producers with Pancreatic Ductal Adenocarcinoma, 08 January 2025, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-5738775/v1] |
Abstracts |
1. Kamgar M, Esteghamati A, Froutan H, Khalilzadeh O. Disturbances of PTH-vitamin D axis in noncholestatic chronic liver diseases.EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2009, 14, 130-130. 20th European Students ́ Conference (ESC), Berlin, Germany, 2009. |
2. Emami S, Kuo HT, Huang E, Kamgar M, Pham PT, Wilkinson A, Bunnapradist S. Antibody Induction Therapy and Their Associated Outcomes in Live Donor Kidney Transplant in Recent Era. AMERICAN JOURNAL OF TRANSPLANTATION 11, 249-250. American Transplant Congress ; Philadelphia, May 2011. |
3. Leeaphorn N, Nata N, Kamgar M, Huang E, Kalantar-Zadeh K, Kaplan B, Bunnapradist S. Post-renal Transplant Outcome in Kidney Waitlist Candidates with Inactive Status Due to Being Temporarily Too Sick. American Transplant Congress (ATC). Oral Presentation; Boston, July 2012.
|
4. Kamgar M, Huang E, Kamgar M, Nata N, Leeaphorn, N, Kalantar-Zadeh K, Schulze C, Bunnapradist S. Zero-mismatch Deceased Donor Kidney Transplantation: A Wise Option for Adult Type 1 Diabetics with End Stage Renal Disease? AMERICAN JOURNAL OF TRANSPLANTATION 12, 104-105. ATC, Oral Presentation; Boston, July 2012 |
5. Schulze C, Kamgar M, Nata N, Leearphron N, Pham PT, Danovitch G, Huang E, Bunnapradist S. Patients on the simultaneous pancreas-kidney transplant waitlist who are not transplanted within the first few years of initial listing suffer from substantial mortality and low likelihood of subsequent transplantation. AMERICAN JOURNAL OF TRANSPLANTATION 11, 249-250. American Transplant Congress (ATC). Oral Presentation; Boston, July 2012. |
6. Nata N, Lau C, Huang E, Kamgar M, Sampaio M, Kalantar-Zadeh K, Bunnapradist S. Outcomes of Simultaneous Pancreas-kidney Re-transplantation After a First Simultaneous pancreas-Kidney Transplant; ASNKidney Week, Poster Presentation; San Diego, October 2012 |
7. Nata N, Poomipanit N, Huang E, Kamgar M, Sampaio M, Kalantar-Zadeh K, Bunnapradist S. Simultaneous Pancreas-kidney Transplantation Outcomes in Recipients Older than 55 Years; ASN Kidney Week, Poster Presentation; San Diego, October 2012. |
8. Andre ML, Kamgar M, Mehrnia A, Huang E, Bunnapradist S. The effect of Medicare vs. Private Insurance on Access to Kidney Transplantation. JOURNAL OF INVESTIGATIVE MEDICINE 61 (1), 156-156. UCLA Department of Medicine Research Day; Los Angeles 2012. |
9. Shye M, Kamgar M, Mehrnia A, Huang E, Bunnapradist S. Cumulative Incidence and Factors Associated with Return to Active Status among Temporary Inactive Obese Renal Transplant Candidates. AMERICAN JOURNAL OF TRANSPLANTATION 13, 195-195. ATC, Oral Presentation; Seattle, WA, 2013. |
10. Yoosabai A, Mehrnia A, Kamgar M, Sampaio M, Huang E, Bunnapradist S. Risk Factors for Acute Rejection in Heart Transplanted Recipients. Am J Transplant. 2013; 13 (suppl 5). ATC, Poster Presentation; Seattle, May 2013. |
11. Schulze C, Kamgar M, Pham PT, Danovitch G, Huang E, Bunnapradist S. Outcomes on the Simultaneous Pancreas-Kidney (SPK) Transplant Waitlist: a Competing Risk Analysis of the UNOS Database. AMERICAN JOURNAL OF TRANSPLANTATION 13, 155-155. ATC, Oral Presentation; Seattle, May 2013. |
12. Ng G, Faerstain S, Mehrnia A, Kamgar M, Bunnapradist S, Gritsch A. Does Expanded Criteria Donor Kidney Biopsy Predict Five-year Patient and Graft Survival? AMERICAN JOURNAL OF TRANSPLANTATION 13, 197-197. ATC, Oral Presentation; Seattle, May 2013. |
13. Mehrnia A, Kamgar M, Sampaio M S, Huang E, Bunnapradist S. The Effect of Donor Service Area (DSA)-Specific Median Waiting Time on Waitlist Outcomes; American Society of Nephrology (ASN) Kidney Week, Poster Presentation; Atlanta, 2013. |
14. Faerstain S, Ng G, Mehrnia A, Kamgar M, Bunnapradist S, Graciano J, Tan T, Gritsch A. Does Expanded Criteria Donor Kidney Biopsy Predict Five-year Patient and Graft Survival? AMERICAN JOURNAL OF TRANSPLANTATION 13, 408-408. TC, PosterPresentation; Seattle, May 2013. |
15. Ismail H, Mohamed A, Song Y, Abdallah N, Surapaneni M, Kim S, Kamgar M, Mettu J, Akhras A, Ahmed A, Philip PA, Shields AF, Tesfaye AA. Comparison of fluoropyrimidine based (FP)and taxane based platinum doublets (TP) in frontline treatment of patients with metastatic gastroesophageal adenocarcinomas (mGEAC): A retrospective analysis. . J Clin Oncol 35, 2017 (suppl; abstr e15604), ASCO Annual Meeting, Online Publication; Chicago, June 2017. |
16. Kamgar M, Dyson G, Diab M, Tesfaye AA, Korn WM, Shields AF, Philip AP. Comprehensive molecular profiling of patients with pancreatic adenocarcinoma: A single institution’s experience. Journal of Clinical Oncology . 36, no. 15_suppl.e16236. ASCO Annual Meeting, Online Publication; Chicago, June 2018 |
17. Song Y, Mohamed A, Ismail H, Abdallah N, Suprapaneni M, Dyson G, Kamgar M, Akhras A, Mettu J, Ahmed A, Tesfaye AA, Philip PA, Shields AF. Comparative analysis of the effect of bevacizumab maintenance regimens after first-line chemotherapy in patients with metastatic colorectal cancer (MCRC): A single institution experience Journal of Clinical Oncology. 35, no. 15_suppl.e15032. ASCO Annual Meeting, Online Publication; Chicago, June 2018 |
18. Kamgar M, Dyson G, Shields AF, Tesfaye AA, Philip PA, Al-Hallak MN. Comprehensive genomic profiling in metastatic pancreatic adenocarcinoma, correlation with early death versus prolonged survival. . J Clin Oncol 37, 2019 (suppl 4; abstr 282), ASCO Gastrointestinal Cancer symposium, Poster Presentation; San Francisco, January 2019. |
19. Shreenivas AV, Murthy GSG, George B, Thomas JP, Chakrabarti S, Kamgar M, Ritch PS. Impact of tumor histology and socioeconomic factors on survival of patients suffering from malignant vascular tumors of liver and hepatocellular carcinomas: A SEER database analysis. . J Clin Oncol 38: 2020 (suppl; abstr e16612), 2020 ASCO Scientific Program, Online Publication; Virtual, May 2020. |
20. Kamgar M, Assad H, Hastert TA , McLaughlin E, Reding K, Paskett ED, Bea JW, Shadyab AH, Neuhouser ML, Nassir R, Crane TE, Sreeram K, Greenwald MK, Simon MS. Peripheral neuropathy after breast cancer: An analysis of data from the Women’s Health Initiative Life and Longevity After Cancer cohort. J Clin Oncol 38: 2020 (suppl; abstr e24093), 2020 ASCO Scientific Program, Online Publication, Virtual, May 2020. |
21. Jurkowski L, Shreenivas AV, Chakrabarti S, Kamgar M, Thomas JP, Puckett L, Shukla M, Gore E, Evans J, Johnstone CA, Gasparri M, Linsky P, Johnstone D, Dua K, Khan AH, Madhavan S, Szabo A, George B. Association of total neoadjuvant therapy with favorable clinical outcomes in patients with locally advanced esophageal and gastroesophageal junction adenocarcinomas (LA-GEJ CA). Journal of Clinical Oncology. 39 (3_suppl), 231-231. ASCO Gastrointestinal Cancer Symposium; Poster Presentation; Virtual, January 2021 |
22. Shreenivas AV, Annunzio K, Kamgar M, Chakrabarti S, Thomas JP, Madhavan S, Dua K, Khan AH, Hall WA, Erickson B, Christians KK, Clarke CN, Evans DB, Tsai S, Szabo A, Urrutia R, Zimmermann MT, Reddi HV, George B. Impact of KRAS alterations in localized pancreatic cancer (PC). Journal of Clinical Oncology. 39 (3_suppl), 431-431. ASCO Gastrointestinal Cancer Symposium, Poster Presentation; Virtual, January 2021 |
23. Thalji S, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson B, Hall WA, Tolat P, Khan A, Evans DB, Tsai S. CA19-9 Response to 1st-Line Neoadjuvant FOLFIRINOX and 2nd-Line Gemcitabine-Based Chemotherapy in Patients with Operable Pancreatic Cancer ANNALS OF SURGICAL ONCOLOGY. 28 (SUPPL 1), S20-S20. Society of Surgical Oncology (SSO); Oral Presentation; March 2021 |
24. Thalji S, Hall WA, Aldakkak M, Christians K, Clarke CN, George B, Kamgar M, Hunt B, Madhavan S, Kulkarni N, Erickson BA, Evans DB, Tsai S. MAGNITUDE OF CA19-9 DECLINE IN RESPONSE TO NEOADJUVANT CHEMORADIATION IS ASSOCIATED WITH OVERALL SURVIVAL IN PATIENTS WITH PANCREATIC CANCER Gastroenterology. 160 (6), S-902. Digestive Disease Week (DDW), Oral Presentation; Virtual, May 2021 |
25. Mehdi M, Kamgar M, George B, Szabo A, Annunzio K, Taylor BW, Shreenivas AV, Chakrabarti S, Thomas JP, Tsai S, Christians KK, Evans DB, Clarke CN, Hall WA, Erickson B, Ahmed G, Thapa B. Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology. 39 (15_suppl), 4136-4136. ASCO Annual Meeting, Poster Presentation; Virtual, May 2021 |
26. Ahmed G, Annunzio K, Szabo A, Eastwood D, Thapa B, Taylor BW, Tsai S, Christians KK, Clarke CN, Evans DB, Hall WA, Erickson B , Kamgar M, George B. Clinical outcomes in pancreatic ductal adenocarcinoma (PDAC) patients with underlying autoimmune disease (AID). Journal of Clinical Oncology. 39 (15_suppl), e16233-e16233. ASCO Annual Meeting; Online Publication; May 2021 |
27. Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S. ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Ann Surg Oncol. 2023 May;30(5):3022. |
28. Sreeram K, Seaton R, Kamgar M, Assad H, Greenwald MK, Ruterbusch JJ, Beebe-Dimmer JL, Schwartz AG, Simon MS. Prevalence and predictors of peripheral neuropathy after chemotherapy: Outcomes from the Detroit Research on Cancer Survivorship (ROCS) cohort. Journal of Clinical Oncology. 39 (15_suppl), 12069-12069. ASCO Annual Meeting, Oral Presentation; Virtual, May 2021 |
29. Tsai S, Borazanci E, Gulley M, Rashid N, Merker J, Khan AH, Chisholm P, Hunt B, Giorgadze T, Hall WA, Kamgar M, Evans DB, Yeh JJ. Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. AACR Pancreatic Virtual Meeting, Poster Presentation; Sep 2021 |
30. Hall WA, Khan HY, Kamgar M, Tsai S, Christians K, Evans DB, Philip P, Clarke C, George B, Erickson B, Azmi AS. Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy . AACR Pancreatic Virtual Meeting; Poster Presentation; Sep 2021 |
31. Ortiz S, Visotcky A, Banerjee A, Aldakkak M,2 Tsai S, Evans DB, Christians KK, Clarke CN, George B,Shreenivas AV, Kamgar M, Chakrabart Si, Dua K, Khan AH, Erickson B,Hall WA. Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy.International Journal of Radiation Oncology, Biology, Physics. 2021 Nov;111(3S):e66-e67. Poster Presentation. 2021 ASTRO Annual Meeting; Chicago, October 2021. |
32. Mehdi M, Annunzio K, Taylor BW, Szabo A, Shreenivas AV, Chakrabarti S, Thomas JP, Tsai S, Christians KK, Evans DB, Clarke CN, Hall WA, Erickson B, Thapa B, Ahmed G, George B, Kamgar M. Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response. Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 596-596. 2022 ASCO Gastrointestinal Cancer symposium. Poster Presentation; San Francisco, January 2022. |
33. Abid H, Szabo A, Taylor BW, Shreenivas AV, Chakrabarti S, Kamgar M, Thomas JP, George B. Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 191-191. 2022 ASCO Gastrointestinal Cancer symposium. Poster Presentation; San Francisco, January 2022. |
34. George B, Thalji S, Malarkannan S, Kudryashova O, Kravets A, Gusakova M, Kravchenko D, Tychinin D, Frenkel F, Bagaev A, Shin N, Mehdi M, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S. Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer. Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 589-589. 2022 ASCO Gastrointestinal Cancer symposium. Poster Presentation; San Francisco, January 2022. |
35. Shreenivas AV, George B, Thomas JP, Puckett L, Chakrabarti S, Awan M, Straza MW, Hall WA, Loy V, Rilling WS, Hong J, Kamgar M, Tsai S, Gamblin TC, Smolock A, Christians KK, Dougherty K, Danziger N, Durazo F, Ross JS.Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study. Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 474-474. 2022 ASCO Gastrointestinal Cancer symposium. Poster Presentation; San Francisco, January 2022. |
36. McKenna E, Oxencis C, Parish M, Eastwood D, Miller J, Shreenivas AV, Kamgar M, George B, Hal WAl, Erickson B, Ludwig KA, Szabo A, Thomas JP, Chakrabarti S. Survival outcome and treatment response of patients with young-onset locally advanced rectal cancer (YO-LARC) receiving total neoadjuvant therapy (TNT). Survival outcome and treatment response of patients with young-onset locally advanced rectal cancer (YO-LARC) receiving total neoadjuvant therapy (TNT). 2022 ASCO Gastrointestinal Cancer symposium. Poster Presentation; San Francisco, January 2022. |
37. Parish M, Cox R, Thapa B, McKenna E, Oxencis C, Shreenivas AV, Kamgar M, George B, Thomas JP, Chakrabarti S. Clinical course and outcome of patients developing capecitabine-induced non-neutropenic enterocolitis (NNEC): An institutional analysis. Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 656-656. 2022 ASCO Gastrointestinal Cancer symposium. Poster Presentation; San Francisco, January 2022. |
38. Mehdi M, Thalij SZ, Shreenivas AV, Chakrabarti S, Thomas JP, Christians KK, Evans DB, Hall WA, Erickson B, Thapa B, Ahmad G, Yazdanpanah O, Kurzrock R, Aldakkak M, Holden MB, George B, Tsai S, Oxencis C, McFall T, Kamgar M. MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in KRAS-mutated advanced pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology . Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) e16260-e16260. |
39. Thalji SZ, Hall WA, Erickson B, Kamgar M, George B, Christians KK, Clarke CN, Doucette S, Miller J, Hunt B, Giorgadze T, Evans DB, Tsai S. Neoadjuvant radiation case volume and associated with margin-negative resection rates in patients with pancreatic cancer. ournal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) e16281-e16281. ASCO Annual Meeting; Chicago, June 2022. |
40. Chakrabarti S, Parish M, Ruggeri A, Shreenivas A, Kamgar M,Sriram D, Peterson C, Ridolfi T, Ludwig K, Alqwasmi A, Mooney C, Burfeind J, Clarke C, Christians K, Gamblin T, George B, Thomas J. SO-33 Neoadjuvant immunotherapy in gastrointestinal tumors with mismatch repair deficiency: An institutional analysis. Annals of Oncology 33, S371. European Society of Medical Oncology, World Congress on Gastrointestinal Cancer (ESMO GI), Oral Presentation; Barcelona, July 2022 |
41. Thalj SZi, Tsai S, Aldakkak M, Barnes C, Small C, Evans DB, George B, Kamgar M, Dua KS, Christians K, Clarke C, Hong TS, Goodman KA, Herman JM, Wang M, Tchelebi L, Zaorsky NG, Sanford NN , Erickson BA, Hall WA. National Trends in Utilization of Neoadjuvant Radiation for Pancreatic Adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics 114 (3), e201-e202. American Society for Therapeutic Radiology and Oncology (ASTRO) 2022; San Antonio, October 2022. |
42. Janardan A, George B, Ahmed G, Daniel S, Thapa B, Mehdi M, Rein L, Szabo A, Erickson B, Hall WA, Christians KK, Tsai S, Evans DB, Kamgar M. Treatment sequencing for patients with localized duodenal and ampullary adenocarcinoma. Journal of Clinical Oncology 41 (4_suppl), 783-783. ASCO Gastrointestinal Cancer symposium, Poster Presentation; San Francisco, January 2023. |
43. Mehdi M, Thapa B, Szabo A, Ahmed G, Shreenivas AV, Thomas JP, Sriram D, Evans DB, Tsai S, Christians KK, Erickson B, Hall WA, McFall T, Patrick S, George B, Kurzrock R, Kamgar M. ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma.Journal of Clinical Oncology 41 (4_suppl), 754-754. ASCO Gastrointestinal Cancer symposium, Poster Presentation; San Francisco, January 2023. |
44. Kamgar M, Khan HY, Aboukameel A, Bannoura S, Chung BY, Szabo A, Li Y, Al Hallak MN, Philip PA, George B, Christians KK, Evans DB, Tsai S, Erickson B, Luther S, Azmi AS, Hall WA. A Phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinomaJournal of Clinical Oncology 41 (4_suppl), TPS760-TPS760. ASCO Gastrointestinal Cancer symposium, Trial in Progress Poster Presentation; San Francisco, January 2023. |
45. Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S. ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Annals of surgical oncology, 2023, 1-9. Society of Surgical Oncology Annual Meeting; Boston, March 2023. |
46. Aldakkak M, Doucette S, Hunt B, Huang CC, Thalji S, Christians KK, Clarke CN, Kamgar M, George B, Erickson B, Hall WA, Douglas BE, Tsai S. Su1433 REEXAMINING 8TH EDITION OF AMERICAN JOINT COMMITTEE ON CANCER NODAL STAGING AMONG PATIENTS WITH PANCREATIC CANCER FOLLOWING NEOADJUVANT THERAPY. Gastroenterology 164 (6), S-1535. The Society for Surgery for the Alimentary Tract (SSAT) meeting; Chicago, May 2023. |
47. CT080 / 7 - A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma
M. Kamgar1, H. Yar Khan2, A. Aboukameel2, S. F. Bannoura2, B. Y. Chung1, A. Szabo1, Y. Li2, M. Al Hallak2, P. A. Philip3, B. George1, K. K. Christians1, D. B. Evans1, S. Tsai4, B. Erickson1, J. M. Goldberg5, A. S. Azmi2, W. A. Hall1;
1Medical College of Wisconsin, Milwaukee, WI, 2Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 3Henry Ford Cancer Institute, Detroit, MI, 4Ohio State University, Colombus, OH, 5Rafael Holdings Inc, Newark, NJ
|
48. Kamgar M, Khan HY, Aboukameel A, Bannoura S, Chung BY, Szabo A, Li Y, Al Hallak MN, Philip PA, George B, Christians KK, Evans DB, Tsai S, Erickson B, Goldberg JM, Azmi AS, Hall WA. Abstract CT080: A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma. Cancer Res (2024) 84 (7_Supplement): CT080. AACR Annual Meeting; San Diego, April 2024. |
49. Auckley E, Ying G, Yohay S, Aldakkak M, Thalji SZ, Vakili P, Grahl J, Mayer B, Shahjehan F, Low SK, Evans DB, Christians KK, Seo YD, Erickson B, Hall WA, McFall T, Kurzrock R, George B, Kamgar M. MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with KRAS G12R alteration. . . |
50. Low SK, Thalji S, Aldakkak M, Ying G, Yohay S, Auckley E, Vakili P, Shahjehan F , Evans DB , Christians KK , Seo YD, Erickson B, Small C , Heyer V, Neupane B, George B, Kothari A, Hall WA , Kamgar M. Impact of neoadjuvant radiation therapy modalities on post-surgical lymphopenia in operable pancreatic cancer. . Clin Oncol 43, 2025 (suppl 4; abstr 710), ASCO Gastrointestinal Cancer symposium, Poster Presentation; San Francisco, January 2025. |
51. Yohay S, Ying G, Auckley E, Aldakkak M, Thalji SZ, Vakili P, Grahl J, Mayer B, Shahjehan F, Low SK, Evans DB, Christians KK, Seo YD, Erickson B, Hall WA, McFall T, Kurzrock R, George B, Kamgar M. MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with KRAS G12D or KRAS G12V alteration. . Clin Oncol 43, 2025 (suppl 4; abstr 726), ASCO Gastrointestinal Cancer symposium, Poster Presentation; San Francisco, January 2025. |
52. K Feustel, L Rein, A Phan, M Kamgar, R Kurzrock, A Szabo, B George. Abstract A008: Intracranial metastases in patients with Claudin 18.2 positive metastatic gastroesophageal cancers. Cancer Research 85 (5_Supplement), A008-A008.
|
53. McFall T, Kamgar M; Abstract B096: Mutant and Wildtype RAS Crosstalk and Stoichiometric Deficiencies Determine Sensitivity to RAS Pathway Targeted Therapies. Cancer Res (2025) 85 (18_Supplement_3): B096. Poster Presentation at: AACR Pancreatic, Boston, USA, September 2025. |
54. Chandrashekhar N, Yuan J, Stasny N, Aldakkak M, Kamgar M, McFall T, Lytle N, Grewal J, Stark A, Guerra O, Phan A, Hall WA, Erickson B, Kothari A, Clarke CN, Christians K, Rilling W, Tolat P, Evans DB, Seo YD; Abstract B008: Ex-vivo organotypic tumor model of metastatic core biopsy serve as a pragmatic platform for real-time personalized therapy in pancreatic adenocarcinoma. Cancer Res (2025) 85 (18_Supplement_3): B008. Poster Presentational: AACR Pancreatic, Boston, USA, September 2025 |
Non-Peer Reviewed Educational Products |
1. Ramon J, Thapa B, Kamgar M. Germline Testing in Pancreatic Ductal Adenocarcinoma Patients. Poster presented at: 2023 SPARCC Cancer Research Summit, Milwaukee, WI |
